<i>LPA</i> Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins

201891 citationsReviewbronze Open Access

Authors

Wei‐Qi Wei · Vanderbilt University Medical Center

Xiaohui Li · UCLA Medical Center

QiPing Feng · Vanderbilt University Medical Center

Michiaki Kubo · RIKEN Center for Integrative Medical Sciences

Iftikhar J. Kullo · Mayo Clinic

Peggy Peissig · Marshfield Clinic

Elizabeth W. Karlson

Abstract

Genetic variations at the LPA locus are associated with CHD events during statin therapy independently of the extent of low-density lipoprotein cholesterol lowering. This finding provides support for exploring strategies targeting circulating concentrations of lipoprotein(a) to reduce CHD events in patients receiving statins.

Topics & Keywords

Lipoproteins and Cardiovascular Health Genetic Associations and Epidemiology Cancer, Lipids, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 138, Issue 17, pp. 1839-1849

DOI: 10.1161/circulationaha.117.031356

Field-Weighted Citation Impact: 11.16